Mesothelin-Expressing TumorsPhase 1NCT06623396Papers
M28z1XXPD1DNR CAR
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
What the film says
This trial is for adults with metastatic hormone receptor positive breast cancer that has progressed on a CDK4/6 inhibitor and hormonal therapy.
The idea: add avasopasem to the CDK4/6 inhibitor and hormonal therapy patients are already taking. The study looks at the safety of the combination and whether adding avasopasem improves how well the treatment works.
This phase 1 study plans 35 patients. At UT Health San Antonio, Kate Lathrop leads it.
Public record; not medical advice.
Sources behind this film
Adults; metastatic HR+ breast cancer progressed on CDK4/6 inhibitor and hormonal therapy; Add avasopasem to ongoing CDK4/6 inhibitor and hormonal therapy; Safety and whether addition improves effectiveness; Phase 1; 35 patients (+1 more lines)
The drug
Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy
This is a phase 1 non-randomized clinical trial of Avasopasem in patients with metastatic hormone receptor positive breast cancer with progression on first line therapy consisting of a CDK 4/6 inhibitor and hormonal therapy to determine the efficacy and safety of the addition of Avasopasem in patients with metastatic HR+ breast cancer with progression after first line treatment with hormonal therapy (an AI or fulvestrant) and a CDK 4/6 inhibitor (ribociclib or abemaciclib).
Each treatment cycle will be 28 days and tumor assessment by imaging with CT scans of the chest, abdomen and pelvis will be performed every two cycles.
The study
This study aims to evaluate the safety of avasopasem in combination with CDK 4/6 inhibitor and hormonal therapy in women with metastatic hormone receptor positive breast cancer, and to see if the addition of avasopasem improves the effectiveness of a CDK 4/6 inhibitor and hormonal therapy.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.